🇺🇸 FDA
Pipeline program

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

SSGJ-613-AG-III-01

Phase 3 small_molecule active

Quick answer

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg for Acute Gout is a Phase 3 program (small_molecule) at Sunshine Biopharma with 2 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Acute Gout
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials